首页> 外文期刊>Journal of clinical gastroenterology >Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Acute Diarrhea A Multicenter, Randomized Study in Primary Care
【24h】

Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Acute Diarrhea A Multicenter, Randomized Study in Primary Care

机译:一种新的共生制剂Flortec在急性腹泻患者中的功效的临床试验一项多中心,初级保健随机研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: Few randomized studies have been carried out on adult patients affected by acute diarrhea especially in primary care, which is the natural context for this kind of disorder. Lactobacillus paracasei B 21060 is a novel strain of lactobacillus, which has been shown to be effective in relieving symptoms associated with diarrhea of irritable bowel syndrome subtype and in shortening diarrhea duration. In this study, we compared the therapeutic efficacy, safety, and tolerability of a new symbiotic formulation, Flortec, containing L. paracasei B-21060, with lactobacillus GG (FlorVis GG) in the treatment of acute presumed infectious diarrhea.
机译:目的:很少对受急性腹泻影响的成年患者进行随机研究,尤其是在初级保健中,这是这种疾病的自然背景。副干酪乳杆菌B 21060是一种新型乳酸菌菌株,已显示可有效缓解与肠易激综合症亚型腹泻有关的症状并缩短腹泻持续时间。在这项研究中,我们比较了含有副干酪乳杆菌B-21060的新型共生制剂Flortec与乳杆菌GG(FlorVis GG)的治疗功效,安全性和耐受性,以治疗急性推测的传染性腹泻。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号